Neuromodulator Brand Switching: Real-World Migration Patterns Across 5 Toxins
Longitudinal tracking of 3,600 neuromodulator patients over 18 months reveals distinct brand migration corridors, with Botox-to-Dysport as the highest-volume switch path driven by cost sensitivity and onset preference. DAXXIFY captures a disproportionate share of multi-brand cyclers but shows 22% reverse migration back to legacy toxins, predominantly among patients whose event-driven treatment timing conflicts with its longer onset window.